DM
DeLong Mark Jeffrey Chief Business & Strat Officer
CEO M
US US · SEC (Form 4)
Browse the full record of transactions filed by DeLong Mark Jeffrey, Chief Business & Strat Officer. Officer active across 2 companies, notably Apellis Pharmaceuticals, Inc.. Cumulatively, 21 disclosures have been recorded. The latest transaction was filed on 16 June 2022 — Levée d'options. Regulator: SEC (Form 4). The full history is openly available.
Declarations 21 total
114,591 shares
Common Stock
SEC:0001193125-26-224597 · 14 May 2026
114,591 shares
Common Stock
SEC:0001193125-26-224597:0 · 14 May 2026
€131,319 10,000 shares @ €13.1319 0.0025% mcap 29.0% of flow
Common Stock
SEC:0001127602-22-017896:0 · 16 Jun 2022
€100,130 7,000 shares @ €14.3043 0.0019% mcap 22.1% of flow
Common Stock
SEC:0001127602-22-012442:0 · 20 Apr 2022
€11,180 271 shares @ €41.2554 0.0002% mcap 2.5% of flow
Common Stock
SEC:0001127602-22-004770:0 · 10 Feb 2022
013,913 shares 0
Common Stock
SEC:0000899243-22-005089 · 21 Jan 2022
013,913 shares 0
Common Stock
SEC:0000899243-22-005089:0 · 21 Jan 2022
€15,025 434 shares @ €34.6191 0.0003% mcap 16.2% of flow
Common Stock
SEC:0001127602-22-002816 · 28 Jan 2022
€15,025 434 shares @ €34.6191 0.0003% mcap 3.3% of flow
Common Stock
SEC:0001127602-22-002816:0 · 28 Jan 2022
010,592 shares 0
Common Stock
SEC:0001127602-22-002057:0 · 21 Jan 2022
010,592 shares 0
Common Stock
SEC:0001127602-22-002057 · 21 Jan 2022
0882 shares 0
Common Stock
SEC:0001127602-21-027697 · 20 Oct 2021
0882 shares 0
Common Stock
SEC:0001127602-21-027697:0 · 20 Oct 2021
€13,161 1,000 shares @ €13.1607 0.0003% mcap 14.2% of flow
Common Stock
SEC:0001127602-21-022382 · 21 Jul 2021
€13,161 1,000 shares @ €13.1607 0.0003% mcap 2.9% of flow
Common Stock
SEC:0001127602-21-022382:0 · 21 Jul 2021
€13,139 1,000 shares @ €13.1394 0.0003% mcap 14.2% of flow
Common Stock
SEC:0001127602-21-022141 · 15 Jul 2021
€13,139 1,000 shares @ €13.1394 0.0003% mcap 2.9% of flow
Common Stock
SEC:0001127602-21-022141:0 · 15 Jul 2021
€51,191 4,000 shares @ €12.7978 0.0010% mcap 55.3% of flow
Common Stock
SEC:0001127602-21-020052 · 15 Jun 2021
€51,191 4,000 shares @ €12.7978 0.0010% mcap 11.3% of flow
Common Stock
SEC:0001127602-21-020052:0 · 15 Jun 2021
€25,393 2,000 shares @ €12.6963 0.0008% mcap 100.0% of flow
Common Stock
SEC:0001127602-21-017369 · 18 May 2021
€25,393 2,000 shares @ €12.6963 0.0005% mcap 5.6% of flow
Common Stock
SEC:0001127602-21-017369:0 · 18 May 2021
About DeLong Mark Jeffrey Mark Jeffrey DeLong is the Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc.